News Releases

- Commences Trading on NASDAQ Global Market on July 25, 2017 under Ticker Symbol “ALPN” - - Utilizes Novel Protein-Based Immunotherapy Discovery Platform Focused on Developing Therapeutics for the Potential Treatment of Inflammatory Diseases and Cancer - - Approximately $90 Million in Cash and Cash

Boulder, CO, July 20, 2017 – Nivalis Therapeutics, Inc. (Nivalis) (Nasdaq:NVLS) announced today that, based upon the final vote count certified by the independent inspector of elections for the special meeting of stockholders held July 19, 2017, its stockholders approved all of the merger-related

SEATTLE, Wash., June 14, 2017 – Alpine Immune Sciences, Inc. (Alpine), a biotechnology company developing a next-generation immune modulation platform, today announced results from a preclinical study evaluating first-generation variant Ig domains (vIgDs™) from the company’s lead program, ALPN-101.

– Plan to Accelerate Development of Novel Immunotherapies Focused on Inflammation and Immuno-Oncology – – Combined Company Well Capitalized with $90 Million in Funding to Advance Discovery and Development – – Existing Investors OrbiMed Advisors, Frazier Healthcare Partners, and Alpine BioVentures

The large number of Immunoglobulin Super Family (IgSF) receptors on immune cells and tumors are attractive targets for development of cancer immunotherapies. While nearly all commercial strategies targeting this family are focused on antibody based biologics, we have developed a novel affinity

Company will leverage its proprietary vIgDTM platform using directed evolution to create novel, multi‐functional first in class immunotherapies SEATTLE, Wash., June 13, 2016 – Alpine Immune Sciences, Inc., (AIS), a privately held biotechnology company developing a next‐generation immune system

Most biotechs go after a launch round and then look for a high-profile industry collaboration. But most biotechs aren’t run by Mitch Gold. The former Dendreon CEO and current venture capitalist has pieced together a $48 million A round for Alpine Immune Sciences in Seattle, which will now look to

A biotechnology company in Seattle led by former Dendreon CEO Mitchell Gold has netted $48 million in funding, marking the region’s largest biotech funding so far this year. Alpine Immune Sciences was formed out of health-care investment fund Alpine BioVentures, also co-founded by Gold.

Mitch Gold will be forever known as the guy who led Dendreon on a controversial roller coaster ride in cancer immunotherapy. Now he’s moved on, and raised a big chunk of money for a startup called Alpine Immune Sciences . Seattle-based Alpine Immune Sciences is announcing today it has raised $48